Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growthZymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicile resolutionTo vote, contact Kingsdale Advisors.
Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future. | September 8, 2022
05.01.2022 - Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or . Seite 1